|
1
|
The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications.
|
Curr Cancer Drug Targets
|
2008
|
3.36
|
|
2
|
PTEN, more than the AKT pathway.
|
Carcinogenesis
|
2007
|
2.70
|
|
3
|
Mice expressing myrAKT1 in the mammary gland develop carcinogen-induced ER-positive mammary tumors that mimic human breast cancer.
|
Carcinogenesis
|
2006
|
1.03
|
|
4
|
Activation of phosphatidylinositol 3-kinase by membrane localization of p110alpha predisposes mammary glands to neoplastic transformation.
|
Cancer Res
|
2008
|
0.97
|
|
5
|
Levels of p27(kip1) determine Aplidin sensitivity.
|
Mol Cancer Ther
|
2007
|
0.94
|
|
6
|
MAP17 enhances the malignant behavior of tumor cells through ROS increase.
|
Carcinogenesis
|
2007
|
0.93
|
|
7
|
PPP1CA contributes to the senescence program induced by oncogenic Ras.
|
Carcinogenesis
|
2008
|
0.92
|
|
8
|
MAP17 overexpression is a common characteristic of carcinomas.
|
Carcinogenesis
|
2007
|
0.92
|
|
9
|
Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53.
|
J Cell Biochem
|
2007
|
0.91
|
|
10
|
Loss-of-function genetic screening identifies a cluster of ribosomal proteins regulating p53 function.
|
Carcinogenesis
|
2008
|
0.87
|
|
11
|
Characterization of the p53 response to oncogene-induced senescence.
|
PLoS One
|
2008
|
0.86
|
|
12
|
MAP17 inhibits Myc-induced apoptosis through PI3K/AKT pathway activation.
|
Carcinogenesis
|
2007
|
0.86
|
|
13
|
Inhibition of phosphatidylinositol-3-kinase synergizes with gemcitabine in low-passage tumor cell lines correlating with Bax translocation to the mitochondria.
|
Anticancer Drugs
|
2005
|
0.84
|
|
14
|
Mst1, RanBP2 and eIF4G are new markers for in vivo PI3K activation in murine and human prostate.
|
Carcinogenesis
|
2007
|
0.77
|